Precision healthcare in the Asia-Pacific region has seen a surge in advancements within the last 12 months; including NGS and laboratory-based tests, approvals (like a companion diagnostic test for lung cancer), and evolving regulations.  

The World Companion Diagnostics & Liquid Biopsy Summit APAC provides an opportunity to unite with your fellow biopharma, diagnostic providers and leading academics to navigate liquid biopsy and companion diagnostic testing and ensure precision therapies become accessible to all patients. 

Join 100+ of your colleagues working within Precision Medicine, Companion Diagnostics, Medical Affairs and Commercialization from China, Japan, Australia, Singapore and more to accelerate the co-development of drug-CDx combinations and liquid biopsy testing to deliver life changing therapies to patients.